Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

aspirin /d

Phase 3Small molecule

TThe First Affiliated Hospital with Nanjing Medical University

aspirin /d is one of 66 small molecule programs targeting Complication. It is currently in Phase 3.

3

Indications

17

Total Trials

3

Active Trials

65

Competitors

Pipeline

Status by Indication[3][1]

Indication

DrugUnknown status

MigraineActive, not recruiting

DrugPreclinical

Unknown status

MigrainePhase 3

Active, not recruiting

Competition

Competitive Landscape

105 competitors in Migraine

#DrugCompanyPhaseTrials

Zonegran

AAzurity Pharmaceuticals

aspirin /d

TThe First Affiliated Hospital with Nanjing Medical University

Elismetrep

Flunarizine

AAspartes Pharmaceuticals, Inc.

BAT7104

Tizanidine Hydrochloride

EElan Pharmaceuticals

Bayer Aspirin

Cymbalta

Jazz Pharmaceuticals

Adempas

Cervidil

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Antiplatelet Therapy2 trials

Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events

Completed·SSeung-Jung Park·Phase 4·NCT02939872·238 enrolled

the Efficacy and Safety of Indobufen and Low-dose Aspirin in Different Regimens of Antiplatelet Therapy

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT03230851·210 enrolled

Coronary Atherosclerosis1 trial

A Comparative Study of Indobufen and Aspirin in Patients With Coronary Atherosclerosis

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT05105750·60 enrolled

Platelet Reactivity1 trial

Platelet Reactivity in PAD Undergoing Percutaneous Angioplasty

Unknown status·CClinical Centre of Serbia··NCT04165629·450 enrolled

Atrial Appendage1 trial

Efficacy of Different Anti-Thrombotic Strategies on the Incidence of Silent Cerebral Embolism After Percutaneous Left Atrial Appendage Occlusion

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT05671276·150 enrolled

Anticoagulation1 trial

Anticoagulation in Blunt Cerebrovascular Injuries

Withdrawn·—·N/A·NCT00494156

10 more indications

Drug1 trial

Anti-Platelet Drugs and Brain-derived Neurotrophic Factor (BDNF) in Human Serum and Plasma

Unknown status·UUniversity of Rostock·N/A·NCT01264640·25 enrolled

Complication1 trial

Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.

Active, not recruiting·PPetrovsky National Research Centre of Surgery··NCT07358416·500 enrolled

Peripheral Arterial Disease1 trial

Ticagrelor and Peripheral Arterial Disease

Terminated·—·Phase 4·NCT02407314·26 enrolled

Aneurysm1 trial

Study of Antiplatelet Therapy for Intracranial Aneurysm Stent-assisted Coiling

Unknown status·—·Phase 4·NCT02224131·1,856 enrolled

Dual Antiplatelet Therapy1 trial

Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 4·NCT00822536·1,798 enrolled

Cognition1 trial

NeuroCognition After Carotid Recanalization

Completed·—·Phase 2·NCT04219774·25 enrolled

ISS1 trial

VISSIT Intracranial Stent Study for Ischemic Therapy

Terminated·CCodman & Shurtleff·Phase 2/3·NCT00816166·125 enrolled

Atrial Fibrillation1 trial

A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure

Unknown status·SScripps Health·Phase 4·NCT03088072·75 enrolled

Migraine1 trial

Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine

Active, not recruiting·GGuangdong Provincial People's Hospital·Phase 3·NCT04946734·440 enrolled

Unspecified2 trials

Ticagrelore Alone Post PCI

Recruiting·SShiraz University of Medical Sciences·Phase 4·NCT06509893·5,400 enrolled

Reversal of the Anti-platelet Effects of Ticagrelor

Completed·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT02383771·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for aspirin /d. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — aspirin /d compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for aspirin /d. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital with Nanjing Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TThe First Affiliated Hospital with Nanjing Medical University

Related News